ADMA Biologics logo

ADMA BiologicsNASDAQ: ADMA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 October 2013

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$5.06 B
-6%vs. 3y high
89%vs. sector
-46%vs. 3y high
88%vs. sector
-12%vs. 3y high
97%vs. sector
-6%vs. 3y high
81%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:33:22 GMT
$21.40$0.00(0.00%)

Dividend

No data over the past 3 years
$119.84 M$113.40 M
$119.84 M$35.91 M

Analysts recommendations

Institutional Ownership

ADMA Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm
accesswire.com20 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
accesswire.com19 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High?
zacks.com18 November 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Urged To Contact The Schall Law Firm
accesswire.com18 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Law Violations
accesswire.com17 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm
accesswire.com16 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Violating Securities Laws
accesswire.com15 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
zacks.com15 November 2024 Sentiment: NEUTRAL

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
accesswire.com14 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

What type of business is ADMA Biologics?

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

What sector is ADMA Biologics in?

ADMA Biologics is in the Healthcare sector

What industry is ADMA Biologics in?

ADMA Biologics is in the Biotechnology industry

What country is ADMA Biologics from?

ADMA Biologics is headquartered in United States

When did ADMA Biologics go public?

ADMA Biologics initial public offering (IPO) was on 17 October 2013

What is ADMA Biologics website?

https://www.admabiologics.com

Is ADMA Biologics in the S&P 500?

No, ADMA Biologics is not included in the S&P 500 index

Is ADMA Biologics in the NASDAQ 100?

No, ADMA Biologics is not included in the NASDAQ 100 index

Is ADMA Biologics in the Dow Jones?

No, ADMA Biologics is not included in the Dow Jones index

When was ADMA Biologics the previous earnings report?

No data

When does ADMA Biologics earnings report?

The next expected earnings date for ADMA Biologics is 28 February 2025